Form 4: CalciMedica Chief Scientific Officer's Spouse Acquires Company Stock

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reported an indirect acquisition of 1,000 shares of common stock by his spouse at a price of $1.85 per share.

Summary

• Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reported a transaction involving the company's common stock.
• On July 1, 2025, 1,000 shares of CalciMedica common stock were acquired indirectly by Mr. Stauderman's spouse.
• The acquisition price for these shares was $1.85 per share.
• Following this transaction, Mr. Stauderman beneficially owns 1,000 shares indirectly through his spouse and 11,944 shares directly, totaling 12,944 shares.

Sentiment

Score: 7

Explanation: The insider purchase by a key executive's spouse indicates a positive sentiment towards the company's future, though the transaction size is modest.

Positives

• An insider, the Chief Scientific Officer, or his spouse, is purchasing company stock, which often signals confidence in the company's future prospects.
• The purchase price of $1.85 per share indicates a specific valuation at which the insider found the stock attractive.

Negatives

• The transaction size of 1,000 shares is relatively small, which might limit its signal strength compared to larger insider purchases.

Industry Context

Insider purchases, especially by high-ranking officers like a Chief Scientific Officer, can be viewed positively across industries as they suggest management's belief in the company's intrinsic value and future performance. In the biotechnology sector, such purchases might signal confidence in ongoing clinical trials, regulatory approvals, or product development milestones.

Related Party Transactions

• The acquisition of 1,000 shares by the spouse of the Chief Scientific Officer is a related party transaction, as it involves an immediate family member of a key executive.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of future stock performance and management confidence, potentially increasing investor confidence.
• Employees: Could interpret the insider purchase as a sign of stability and positive outlook for the company.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, Insider Trading, Form 4, Stock Purchase, Kenneth A. Stauderman, Chief Scientific Officer, Equity Acquisition, Biotechnology, Pharmaceuticals